A Novel AI-Guided Hormone Replacement System Engineered to Maintain Physiologic Levels of 17β Estradiol and Progesterone

Some cases of primary and secondary amenorrhea are associated with significant symptoms and an increased risk of multiple diseases, including cardiovascular disease (CVD), osteoporosis, genitourinary dysfunction (urinary urgency and incontinence), vasomotor symptoms such as hot flashes and night sweats, and central nervous system manifestations resulting from estrogen (17-Beta estradiol) deficiency. However, current hormone replacement therapy (HRT) has important limitations in reproducing the physiological actions of endogenous 17-Beta estradiol due to the route of administration, dosing patterns, and adverse effects of synthetic hormones. This paper proposes a novel therapeutic system designed to overcome these limitations. The system consists of two main components: (1) the production of human-identical 17β-estradiol and progesterone using genetically engineered yeast, and (2) the delivery of these hormones via a subcutaneous pump programmed to maintain physiologic pulsatile secretion. An AI model assists in determining the optimal hormone dose and timing for each patient based on individualized parameters such as body weight, SHBG levels, and overall health status.